CD274 and head and neck carcinoma: Similarly, in head and neck carcinoma, STT3B-mediated glycosylation stabilizes the EREG growth factor, promoting PD-L1 upregulation; treatment with the STT3 inhibitor NGI-1 destabilizes EREG and synergizes with anti-PD-L1 therapy.